Journal: European journal of pharmacology

Article Title: PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin.

doi: 10.1016/j.ejphar.2019.172696

Figure Lengend Snippet: Fig. 5. VEGFR-1 signaling mediated autocrine and exogenous PlGF-induced proliferation. (A and B) In vitro proliferative curves of (A) 4T1 and MCF-7 cells, treated with PBS (Con), recombinant PlGF, or in combination of siRNA against VEGFR-1 or VEGFR-2 (n = 6). (C) Immunoblotting for VEGFR-2 of endothelial cell (EC), 4T1 and MCF-7 breast cancer cells. EC is used as the control. (D) Immunostaining for VEGFR-1 (Left) and VEGFR-2 (Right) in 4T1 cells from untreated mouse. (E and F) In vitro proliferation curves of (E) MCF-7 and (F) 4T1 breast cells, treated with PBS (Con), recombinant PlGF or in combination with GDC-0994 (n = 6). Measurement data are expressed as mean ± S.D. **P < 0.01; ***P < 0.001; ns indicates not statistically significant (P > 0.05).

Article Snippet: Recombinant human and mouse PlGF proteins were obtained from R&D SYSTEMs.

Techniques: In Vitro, Recombinant, Western Blot, Control, Immunostaining

Journal: EMBO molecular medicine

Article Title: FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.

doi: 10.1038/s44321-024-00094-2

Figure Lengend Snippet: Figure 2. Talazoparib (Tal)-resistant tumors show increased VEGFR2 (KDR) and PGF expression but only modest sensitization to Tal upon VEGFR2 depletion.

Article Snippet: The slides were further blocked with BSA and goat or rabbit serum (depending on the species of the secondary antibodies), and tissue sections were incubated with primary antibodies, including antibodies against phospho-AKT (S473) (1:100, #4060, Cell Signaling Technology), KDR/VEGFR2 (1:2000, #9698, Cell Signaling Technology), VEGFA (1:300, #AF-493-NA, R&D Systems), PGF (1:300, AF465, R&D Systems), CD8α (1:200, #98941, Cell Signaling Technology), F4/80 (1:500, #70076, Cell Signaling Technology), B220 (1:400, # 553085, BD Pharmingen), CD4 (1:200, #25229, Cell Signaling Technology), CD11C (1:250, #97585, Cell Signaling Technology), FOXP3 (1:100, #12653, Cell Signaling Technology), murine S100A9 (1:1000, #73425, Cell Signaling Technology), FLT4 (1:250, #AF743, R&D Systems), and phospho-Stat3 (S727) (1:100, #9134, Cell Signaling Technology), followed by incubation with the corresponding biotinylated secondary antibodies (1:250, Vector Laboratories).

Techniques: Expressing